
Nervonik, a Los Angeles medical device company developing a peripheral nerve stimulation system for chronic pain, has closed a $52.5 million Series B financing. The round was oversubscribed, according to the company. Aydin Babakhani, who founded Nervonik and serves as its CEO, has built the company around a specific idea: that what makes nerve stimulation therapy fail is not the stimulation itself, but the absence of feedback from the body.
Peripheral nerve stimulation works by placing small electrodes near nerves outside the brain and spinal cord. Those electrodes deliver electrical pulses that interrupt pain signals before they reach the brain. It is a well-established approach, but it has a persistent weakness. For patients who cannot tolerate long-term medication, or whose medications have stopped working, it offers a real alternative. The global market for peripheral nerve stimulators was valued at $1.25 billion in 2025 and is projected to reach $2.18 billion by 2035, as demand grows for pain therapies that do not rely on opioids or invasive surgery.
The Series B was led by Amzak Health. Additional participants include Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital.
Most peripheral nerve stimulation systems in use today deliver electrical pulses with no way to measure what is actually happening inside the body. The device cannot confirm whether it is reaching the right nerve, whether the lead has moved out of position, or whether the stimulation is producing any meaningful biological effect. Clinicians programming these systems depend heavily on what patients report, which varies from person to person and visit to visit.
Nervonik is building its system around a different approach. Rather than delivering stimulation blindly, its platform records electrical signals from the nerve in real time, including what are known as evoked compound action potentials. These are measurable responses that indicate a nerve has actually been activated. By capturing this kind of data, the system can help confirm that therapy is working as intended and allow for more informed adjustments. Nervonik refers to this integration of stimulation and sensing as a closed-loop approach, and positions it within the broader field of bioelectronic medicine, which uses electrical signals to treat disease.
"Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," said Anthony Natale, MD, Partner at Amzak Health. "Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to meaningfully improve the patient experience, and they are exceptionally well-positioned to capitalize on this opportunity. We are excited to lead this financing and to support the company through its next phase of growth."
The new capital will go toward three areas: moving clinical programs forward, building out the path to commercialization, and continuing to develop the company's sensing technology. Nervonik has already completed a first-in-human clinical trial. The Series B is meant to carry it from that early stage toward a product that could eventually reach patients.
Sensing remains the technical priority. Early data from the company's trials show successful recording of evoked compound action potentials through implantable leads, which Nervonik says supports its core hypothesis that real-time nerve feedback is achievable in a practical device. The next phase involves refining that capability and testing it across a broader patient population.
"Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy," said Aydin Babakhani, CEO and Founder of Nervonik. "This financing enables us to accelerate our clinical programs, prepare for commercialization, and bring a truly intelligent, next-generation therapy to the patients who need it most."
Babakhani founded Nervonik and continues to lead it as CEO and board member. The company is based in Los Angeles and works specifically on peripheral nerve stimulation, a category of neuromodulation that targets nerves in the body's limbs and tissues rather than the spinal cord or brain.
The technical foundation of the system is what Nervonik calls its trifecta technology, a patented design the company says removes the main obstacles to biosensing in peripheral nerve stimulation. One of those obstacles is physical. Existing PNS devices were not built for areas of the body that move frequently, and lead instability during activity is a known problem. Nervonik's system is designed with high-motion environments in mind. The team behind it includes engineers and clinicians with backgrounds at established medical device companies, along with a clinical advisory board covering pain management and neuromodulation.
The company has cleared two notable regulatory and clinical hurdles. It received approval to begin a first-in-human study and has since completed it, producing early data that support its sensing approach. That said, Nervonik's technology remains in development. It has not received FDA clearance or approval for commercial sale.
Amzak Health led the Series B. The firm invests in medtech and biotech and describes its role as more than financial, working alongside portfolio companies through development and toward commercial milestones. The remaining participants in the round are Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital.


